Evan David Seigerman
Stock Analyst at BMO Capital
(3.30)
# 978
Out of 5,179 analysts
55
Total ratings
47.92%
Success rate
3.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $120 → $100 | $60.09 | +66.42% | 2 | Feb 17, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $119.63 | +8.67% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $737.71 | +15.22% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $348.77 | +6.66% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $36.04 | +27.64% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $7.22 | +52.35% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $209.40 | +14.61% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $20.35 | +27.76% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $20.75 | +34.94% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $10.10 | -0.99% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $45.92 | +117.77% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $27.04 | +33.14% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $4.81 | -37.63% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $878.24 | -54.91% | 1 | Sep 6, 2022 |
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $120 → $100
Current: $60.09
Upside: +66.42%
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $119.63
Upside: +8.67%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $737.71
Upside: +15.22%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $348.77
Upside: +6.66%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $36.04
Upside: +27.64%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $7.22
Upside: +52.35%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $209.40
Upside: +14.61%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $20.35
Upside: +27.76%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $20.75
Upside: +34.94%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $10.10
Upside: -0.99%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $45.92
Upside: +117.77%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $27.04
Upside: +33.14%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $4.81
Upside: -37.63%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $878.24
Upside: -54.91%